BioCentury | Jun 3, 2013
Company News
Olon S.p.A., Salix deal
...Salix acquired worldwide rights to Olon's IP relating to amorphous rifaximin. The IP includes a pending...
...to amorphous rifaximin. The IP includes a pending patent application and an issued patent that Olon...
...and respiratory indications, including Crohn's disease (see BioCentury, July 8, 1996 & Aug, 13, 2012). Olon S.p.A....
...to amorphous rifaximin. The IP includes a pending patent application and an issued patent that Olon...
...and respiratory indications, including Crohn's disease (see BioCentury, July 8, 1996 & Aug, 13, 2012). Olon S.p.A....
